MAP2

Across TCGA pan-cancer cohorts, MAP2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MAP2 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MAP2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

UCEC, LIHC, and LUAD are the cancer types where MAP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.937	0.617	.006	34	view →
LIHC	DFS	Median	All	0.100	0.534	<.001	8	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.161	0.687	<.001	6	view →
BLCA	OS	Median	IV	0.228	0.602	.020	6	view →
COAD	OS	Median	II,III,IV	0.270	0.679	.008	5	view →
SKCM	OS	Median	III,IV	0.294	0.734	.008	3	view →
HNSC	DFS	Median	All	1.000	0.701	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MAP2–UCEC (DFS)

Open the UCEC breakdown →